BioPorto (BIOPOR) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.249x

Based on the latest financial reports, BioPorto (BIOPOR) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Dkr-15.68 Million ≈ $-2.45 Million USD) by net assets (Dkr63.01 Million ≈ $9.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of BioPorto to measure how many days the company can operate on defensive assets alone.

BioPorto - Cash Flow Conversion Efficiency Trend (2000–2025)

This chart illustrates how BioPorto's cash flow conversion efficiency has evolved over time, based on yearly financial data.

BioPorto Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioPorto ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Streamex Corp
NASDAQ:STEX
-0.023x
Fluent Inc
NASDAQ:FLNT
-0.350x
KEYEAST.Co.Ltd
KQ:054780
-0.060x
CAB Cakaran Corporation Bhd
KLSE:7174
0.245x
ChampionsGate Acquisition Corporation Class A Ordinary Share
NASDAQ:CHPG
0.000x
Agrify Corp
NASDAQ:AGFY
-0.459x
Sarla Performance Fibers Limited
NSE:SARLAPOLY
0.091x
Ecos India Mobility & Hospitality Ltd
NSE:ECOSMOBLTY
0.088x

Annual Cash Flow Conversion Efficiency for BioPorto (2000–2025)

The table below shows the annual cash flow conversion efficiency of BioPorto from 2000 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of BioPorto.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Dkr63.01 Million
≈ $9.86 Million
Dkr-77.07 Million
≈ $-12.06 Million
-1.223x +0.82%
2024-12-31 Dkr67.78 Million
≈ $10.60 Million
Dkr-83.58 Million
≈ $-13.08 Million
-1.233x -33.78%
2023-12-31 Dkr60.16 Million
≈ $9.41 Million
Dkr-55.46 Million
≈ $-8.68 Million
-0.922x -23.33%
2022-12-31 Dkr70.22 Million
≈ $10.99 Million
Dkr-52.48 Million
≈ $-8.21 Million
-0.747x +46.80%
2021-12-31 Dkr45.96 Million
≈ $7.19 Million
Dkr-64.58 Million
≈ $-10.10 Million
-1.405x -298.07%
2020-12-31 Dkr100.91 Million
≈ $15.79 Million
Dkr-35.62 Million
≈ $-5.57 Million
-0.353x +85.15%
2019-12-31 Dkr25.32 Million
≈ $3.96 Million
Dkr-60.16 Million
≈ $-9.41 Million
-2.376x -251.29%
2018-12-31 Dkr56.20 Million
≈ $8.79 Million
Dkr-38.01 Million
≈ $-5.95 Million
-0.676x -28.99%
2017-12-31 Dkr56.07 Million
≈ $8.77 Million
Dkr-29.40 Million
≈ $-4.60 Million
-0.524x -18.13%
2016-12-31 Dkr44.29 Million
≈ $6.93 Million
Dkr-19.66 Million
≈ $-3.08 Million
-0.444x -19.14%
2015-12-31 Dkr44.48 Million
≈ $6.96 Million
Dkr-16.57 Million
≈ $-2.59 Million
-0.373x +33.77%
2014-12-31 Dkr28.69 Million
≈ $4.49 Million
Dkr-16.14 Million
≈ $-2.52 Million
-0.563x -44.91%
2013-12-31 Dkr42.86 Million
≈ $6.71 Million
Dkr-16.64 Million
≈ $-2.60 Million
-0.388x -102.92%
2012-12-31 Dkr-1.15 Million
≈ $-179.93K
Dkr-15.28 Million
≈ $-2.39 Million
13.287x +484.76%
2011-12-31 Dkr3.94 Million
≈ $616.44K
Dkr-13.61 Million
≈ $-2.13 Million
-3.453x +14.59%
2010-12-31 Dkr3.31 Million
≈ $517.72K
Dkr-13.38 Million
≈ $-2.09 Million
-4.043x -368.99%
2009-12-31 Dkr15.41 Million
≈ $2.41 Million
Dkr-13.29 Million
≈ $-2.08 Million
-0.862x +2.57%
2008-12-31 Dkr15.50 Million
≈ $2.43 Million
Dkr-13.72 Million
≈ $-2.15 Million
-0.885x -84.47%
2007-12-31 Dkr29.45 Million
≈ $4.61 Million
Dkr-14.13 Million
≈ $-2.21 Million
-0.480x -62897.70%
2006-12-31 Dkr-17.62 Million
≈ $-2.76 Million
Dkr-13.46K
≈ $-2.11K
0.001x -83.18%
2005-12-31 Dkr-3.06 Million
≈ $-478.13K
Dkr-13.88K
≈ $-2.17K
0.005x -99.19%
2000-12-31 Dkr894.00K
≈ $139.87K
Dkr503.00K
≈ $78.70K
0.563x --

About BioPorto

CO:BIOPOR Denmark Diagnostics & Research
Market Cap
$89.47 Million
Dkr571.84 Million DKK
Market Cap Rank
#19720 Global
#83 in Denmark
Share Price
Dkr1.16
Change (1 day)
-0.43%
52-Week Range
Dkr0.84 - Dkr1.45
All Time High
Dkr7.78
About

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination o… Read more